Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial - PubMed
4 hours ago
- #clinical trial
- #PASC
- #COVID-19
- Neither Metformin nor Ursodeoxycholic Acid (UDCA) effectively treats Postacute Sequelae of COVID-19 (PASC).
- The study was a double-blind, placebo-controlled, randomized clinical trial involving 396 participants with a PASC index score of 12 or greater.
- Participants were divided into three groups: Metformin (1500 mg/d), UDCA (900 mg once daily), or placebo for 14 days.
- Recovery rates at 8 weeks were similar across all groups: 63.6% for Metformin, 68.2% for UDCA, and 68.2% for placebo.
- Changes in PASC scores from baseline to week 8 showed no significant difference between treatment groups and placebo.
- The study's findings may not apply to patients with more severe or persistent long COVID symptoms.
- The trial was funded by the National Institute of Infectious Diseases, National Institute of Health, South Korea.